HUP0303800A3 - Pharmaceuticals and dosage forms of epothilones for oral administration - Google Patents
Pharmaceuticals and dosage forms of epothilones for oral administrationInfo
- Publication number
- HUP0303800A3 HUP0303800A3 HU0303800A HUP0303800A HUP0303800A3 HU P0303800 A3 HUP0303800 A3 HU P0303800A3 HU 0303800 A HU0303800 A HU 0303800A HU P0303800 A HUP0303800 A HU P0303800A HU P0303800 A3 HUP0303800 A3 HU P0303800A3
- Authority
- HU
- Hungary
- Prior art keywords
- epothilones
- pharmaceuticals
- dosage forms
- oral administration
- oral
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26422801P | 2001-01-25 | 2001-01-25 | |
US29001901P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/002518 WO2002058701A1 (en) | 2001-01-25 | 2002-01-25 | Pharmaceutical dosage forms of epothilones for oral administration |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0303800A2 HUP0303800A2 (hu) | 2004-03-29 |
HUP0303800A3 true HUP0303800A3 (en) | 2005-02-28 |
Family
ID=26950349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303800A HUP0303800A3 (en) | 2001-01-25 | 2002-01-25 | Pharmaceuticals and dosage forms of epothilones for oral administration |
Country Status (26)
Country | Link |
---|---|
US (2) | US6576651B2 (hu) |
EP (1) | EP1361877A1 (hu) |
JP (1) | JP2004528287A (hu) |
KR (1) | KR20040025888A (hu) |
CN (1) | CN1268336C (hu) |
AR (1) | AR035078A1 (hu) |
BG (1) | BG108027A (hu) |
BR (1) | BR0206695A (hu) |
CA (1) | CA2434584A1 (hu) |
CZ (1) | CZ20032023A3 (hu) |
EE (1) | EE200300329A (hu) |
HR (1) | HRP20030674A2 (hu) |
HU (1) | HUP0303800A3 (hu) |
IL (1) | IL156759A0 (hu) |
IS (1) | IS6892A (hu) |
MX (1) | MXPA03006476A (hu) |
NO (1) | NO20033343L (hu) |
NZ (1) | NZ526871A (hu) |
PE (1) | PE20020853A1 (hu) |
PL (1) | PL368636A1 (hu) |
RU (1) | RU2291695C2 (hu) |
SK (1) | SK9212003A3 (hu) |
TW (1) | TWI250017B (hu) |
UY (1) | UY27138A1 (hu) |
WO (2) | WO2002058699A1 (hu) |
YU (1) | YU58103A (hu) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6824879B2 (en) | 1999-06-10 | 2004-11-30 | Honeywell International Inc. | Spin-on-glass anti-reflective coatings for photolithography |
CA2374944A1 (en) | 1999-06-10 | 2000-12-21 | Nigel Hacker | Spin-on-glass anti-reflective coatings for photolithography |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
HUP0302567A2 (hu) * | 2001-01-25 | 2003-12-29 | Bristol-Myers Squibb Co. | Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
KR20040025895A (ko) | 2001-02-20 | 2004-03-26 | 브리스톨-마이어스스퀴브컴파니 | 에포틸론 유도체를 사용하는 치료불응성 종양의 치료 |
EE05417B1 (et) * | 2001-03-14 | 2011-06-15 | Bristol-Myers Squibb Company | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias |
AU2002227106A1 (en) | 2001-11-15 | 2003-06-10 | Honeywell International Inc. | Spin-on anti-reflective coatings for photolithography |
US7211593B2 (en) * | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
CZ17621U1 (cs) * | 2003-08-26 | 2007-06-25 | Shire Holdings Ag | Farmaceutický prostredek zahrnující slouceniny lanthanu |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
DK1687066T3 (da) | 2003-11-14 | 2012-11-26 | Brigham & Womens Hospital | Fremgangsmåder til immunmodulering |
US8053159B2 (en) | 2003-11-18 | 2011-11-08 | Honeywell International Inc. | Antireflective coatings for via fill and photolithography applications and methods of preparation thereof |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
PT1817013E (pt) * | 2004-11-18 | 2008-08-07 | Brystol Myers Squibb Company | Pérola com revestimento entérico compreendendo ixabepilona |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
US8642246B2 (en) | 2007-02-26 | 2014-02-04 | Honeywell International Inc. | Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof |
AR071598A1 (es) | 2008-04-24 | 2010-06-30 | Bristol Myers Squibb Co | Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer |
US8557877B2 (en) | 2009-06-10 | 2013-10-15 | Honeywell International Inc. | Anti-reflective coatings for optically transparent substrates |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US8864898B2 (en) | 2011-05-31 | 2014-10-21 | Honeywell International Inc. | Coating formulations for optical elements |
CN102276433B (zh) * | 2011-06-30 | 2016-04-20 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
EP3194502A4 (en) | 2015-04-13 | 2018-05-16 | Honeywell International Inc. | Polysiloxane formulations and coatings for optoelectronic applications |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
ES2218328T5 (es) | 1995-11-17 | 2011-11-11 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Derivados de epotilón, su preparación y utilización. |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
KR100561788B1 (ko) * | 1996-03-12 | 2006-09-20 | 피지-티엑스엘 컴파니,엘.피. | 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치 |
DE19636343C1 (de) * | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
HU229833B1 (en) | 1996-11-18 | 2014-09-29 | Biotechnolog Forschung Gmbh | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1386922B1 (en) * | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
ZA981575B (en) | 1997-02-25 | 1998-09-08 | Biotechnolog Forschung Gmbh | Epothilones which are modified in the side chain |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
DE59805900D1 (de) | 1997-04-18 | 2002-11-14 | Studiengesellschaft Kohle Mbh | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
DE59805727D1 (de) | 1997-07-16 | 2002-10-31 | Schering Ag | Thiazolderivate, verfahren zur herstellung und verwendung |
EP1005465B1 (de) | 1997-08-09 | 2007-07-25 | Bayer Schering Pharma Aktiengesellschaft | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
CN100396276C (zh) | 1998-02-05 | 2008-06-25 | 诺瓦提斯公司 | 依普西龙组合物 |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
WO2000037473A1 (en) | 1998-12-22 | 2000-06-29 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
CN1209360C (zh) | 1999-02-18 | 2005-07-06 | 舍林股份公司 | 16-卤-依泊昔酮衍生物、其制备方法及其医药用途 |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
PL207720B1 (pl) | 2001-01-25 | 2011-01-31 | Bristol Myers Squibb Co | Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej |
EE05417B1 (et) | 2001-03-14 | 2011-06-15 | Bristol-Myers Squibb Company | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias |
-
2002
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Application Discontinuation
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Application Discontinuation
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Application Discontinuation
- 2002-01-25 PL PL02368636A patent/PL368636A1/xx not_active Application Discontinuation
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
-
2003
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-08-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
-
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
USRE40387E1 (en) | 2008-06-17 |
NO20033343D0 (no) | 2003-07-24 |
AR035078A1 (es) | 2004-04-14 |
CN1268336C (zh) | 2006-08-09 |
MXPA03006476A (es) | 2003-09-22 |
IL156759A0 (en) | 2004-02-08 |
JP2004528287A (ja) | 2004-09-16 |
PL368636A1 (en) | 2005-04-04 |
KR20040025888A (ko) | 2004-03-26 |
BG108027A (bg) | 2004-12-30 |
YU58103A (sh) | 2006-03-03 |
RU2003126174A (ru) | 2005-02-27 |
CA2434584A1 (en) | 2002-08-01 |
IS6892A (is) | 2003-07-24 |
WO2002058701A1 (en) | 2002-08-01 |
PE20020853A1 (es) | 2002-09-27 |
RU2291695C2 (ru) | 2007-01-20 |
CN1498106A (zh) | 2004-05-19 |
CZ20032023A3 (cs) | 2005-03-16 |
EE200300329A (et) | 2003-10-15 |
AU2002253880B2 (en) | 2006-11-09 |
TWI250017B (en) | 2006-03-01 |
HRP20030674A2 (en) | 2005-06-30 |
NZ526871A (en) | 2006-01-27 |
SK9212003A3 (en) | 2004-11-03 |
EP1361877A1 (en) | 2003-11-19 |
NO20033343L (no) | 2003-09-24 |
HUP0303800A2 (hu) | 2004-03-29 |
BR0206695A (pt) | 2004-04-20 |
WO2002058699A1 (en) | 2002-08-01 |
US6576651B2 (en) | 2003-06-10 |
UY27138A1 (es) | 2002-08-30 |
US20020177615A1 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303800A3 (en) | Pharmaceuticals and dosage forms of epothilones for oral administration | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
IL166489A (en) | Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone | |
HK1070285A1 (en) | Pharmaceutical dosage form of amorphous nelfinavirmesylate | |
EP1365747A4 (en) | PHARMACEUTICAL PRESENTATION OF ORAL PEPTIDE ADMINISTERED AND METHOD OF PRODUCTION | |
IL162293A0 (en) | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules | |
HK1047231A1 (en) | Oral pharmaceutical forms of administration with adelayed action with tramadol | |
PL396568A1 (pl) | Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny | |
IL162843A0 (en) | Dosage form for oral administration of a pde4 inhibitor | |
GB0117618D0 (en) | Pharmaceutical dosage form | |
PL367180A1 (en) | Stabilized oral pharmaceutical composition | |
EP1372392A4 (en) | ORAL DOSAGE FORM CONTAINING NICOTINE | |
PL372773A1 (en) | Oral administration of epothilones | |
HUP0303998A2 (hu) | Új ftalazinon-származékok és ezeket tartalmazó gyógyszerkészítmények | |
IL166337A0 (en) | Oral administration of calctionin | |
GB0117619D0 (en) | Pharmaceutical dosage form | |
HK1066459A1 (en) | Pharmaceutical dosage form and method of making | |
AU2003276572A1 (en) | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations | |
IL161143A0 (en) | A flash-melt pharmaceutical oral dosage composition | |
HUP0400023A2 (hu) | Új heterociklusos származékok és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
IL162510A0 (en) | Pharmaceutical suspension for oral administration | |
HUP0401862A3 (en) | Novel heterocyclic compound and medicinal use thereof and pharmaceutical compositions containing them | |
IL155855A0 (en) | Pharmaceutical formulation of gepirone for oral administration | |
HUP0401371A3 (en) | Pharmaceutical formulation containing an ltb4 antagonist and process for its preparation | |
AU2002348105A1 (en) | Oral dosage forms for improving the bioavailability of therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |